| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/31/2000 | CA2363621A1 A novel inhibitor of programmed cell death |
| 08/31/2000 | CA2363106A1 Mdm interacting protein and methods of use thereof |
| 08/31/2000 | CA2362906A1 Dna encoding snorf25 receptor |
| 08/31/2000 | CA2362533A1 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | CA2362520A1 Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase |
| 08/31/2000 | CA2362047A1 Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started |
| 08/31/2000 | CA2361828A1 Anti-tumor synergetic composition |
| 08/31/2000 | CA2361826A1 Antitumour synergistic composition |
| 08/31/2000 | CA2361396A1 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene |
| 08/31/2000 | CA2355241A1 Bioadhesive antibacterial wound healing composition |
| 08/30/2000 | EP1031348A2 Interleukin-4 production inhibitors |
| 08/30/2000 | EP1030929A1 Transfection and transfer of male germ cells for generation of transgenic species |
| 08/30/2000 | EP1030926A2 Transgenic models of inflammatory disease |
| 08/30/2000 | EP1030917A1 Transcriptionally regulated g protein-coupled receptor |
| 08/30/2000 | EP1030915A1 A novel gene and uses therefor |
| 08/30/2000 | EP1030911A1 Human aspartic proteases |
| 08/30/2000 | EP1030865A2 Th2 CELL DEPLETION; COMPOSITIONS; METHODS |
| 08/30/2000 | EP1030859A1 Ras-binding protein (pre1) |
| 08/30/2000 | EP1030839A1 Use of alkylated iminosugars to treat multidrug resistance |
| 08/30/2000 | EP1030734A1 Encapsulate of active material in alginate matrix |
| 08/30/2000 | EP1030685A2 Essential bacterial genes and their use |
| 08/30/2000 | EP1030682A1 Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor |
| 08/30/2000 | EP1030679A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator |
| 08/30/2000 | EP1030677A1 Synergetic oral composition combining sulphuric chondroitin acid and/or dna with hydroxyproline |
| 08/30/2000 | EP1030674A1 METHODS FOR TREATMENT OF TUMORS AND TUMOR CELLS USING $i(EX VIVO) ACTIVATED T CELLS |
| 08/30/2000 | EP1030672A1 Method for treating attention deficit disorder |
| 08/30/2000 | EP1030671A1 Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia |
| 08/30/2000 | EP1030670A1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 08/30/2000 | EP1030666A1 Novel use of compounds for anti-pruritic activity |
| 08/30/2000 | EP1030662A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |
| 08/30/2000 | EP1030656A1 Administering active substances by using the capsid produced out of the polyoma virus vp1 protein |
| 08/30/2000 | EP0831876A4 Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| 08/30/2000 | CN1265035A Method for inhibiting bone resorption |
| 08/29/2000 | US6111089 Nucleic acid encoding a defined mouse amino acid sequence of a protein involved in embryo implantation; vaccine can be used as antifertility agent |
| 08/29/2000 | US6111074 Amino acid sequence of polypeptide from the uridine monophosphate kinase family; for screening bactericides and bacteriostats; for diagnosis and prophylaxis of infections |
| 08/29/2000 | US6110974 Administering optically pure eutomer of adrenergic beta-2 agonist albuterol, while minimizing or eliminating side effects residing in the corresponding distomer |
| 08/29/2000 | US6110912 Administering to eye of patient a serine-threonine kinase inhibitor to enhance aqueous humor outflow |
| 08/29/2000 | US6110901 3'-deoxyribocytosine, 3'-deoxyribouracil, and/or 3'-deoxyriboguanine |
| 08/29/2000 | US6110692 Receptor for underivatized aqueous soluble β(1-3)-glucan |
| 08/29/2000 | US6110686 DNA hybridizing to a human cystatin-like protein (CSTIN) |
| 08/29/2000 | US6110672 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 08/29/2000 | US6110475 Compostion, barrier film, and method for preventing contact dermatitis |
| 08/29/2000 | US6110471 Administering phosphodiesterase for inhibition of the cycles |
| 08/29/2000 | US6110460 Methods of using morphogen analogs |
| 08/26/2000 | CA2298877A1 Use of mesophase-stabilized compositions for delivery of cholesterol-reducing sterols and stanols in food products |
| 08/24/2000 | WO2000049144A2 Pyk2 binding proteins |
| 08/24/2000 | WO2000049043A2 Human lipid-associated proteins |
| 08/24/2000 | WO2000049037A1 Growth hormone secretagogues |
| 08/24/2000 | WO2000048989A1 Mevinolin derivatives |
| 08/24/2000 | WO2000048643A1 Biodegradable, injectable oligomer-polymer composition |
| 08/24/2000 | WO2000048632A1 Novel redox clamping agents and uses thereof |
| 08/24/2000 | WO2000048631A2 Adjuvant and cell maturation agent |
| 08/24/2000 | WO2000048627A1 Inhibitors of separin, method for identifying them and uses |
| 08/24/2000 | WO2000048625A2 Inhibitors for use in hemostasis and immune function |
| 08/24/2000 | WO2000048621A2 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | WO2000048617A2 Connective tissue softening |
| 08/24/2000 | WO2000048606A1 Compositions and methods for use in targeting vascular destruction |
| 08/24/2000 | WO2000048603A1 DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS |
| 08/24/2000 | WO2000048597A1 Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
| 08/24/2000 | WO2000048591A1 Combinations for the treatment of diseases involving angiogenesis |
| 08/24/2000 | WO2000048583A2 Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine |
| 08/24/2000 | WO2000048581A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 08/24/2000 | WO2000048578A1 Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same |
| 08/24/2000 | WO2000048572A1 Phosphocholine linked prodrug derivatives |
| 08/24/2000 | WO2000048558A1 Modified calycins |
| 08/24/2000 | WO2000048541A1 Zinc chloride in treating skin diseases |
| 08/24/2000 | WO2000048447A2 Composition for treatment of external secretion disorders except hypolacrimation |
| 08/24/2000 | WO2000048446A2 Use of antagonists of pg-e for the treatment of neuropathic pain |
| 08/24/2000 | WO2000027380A3 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| 08/24/2000 | WO2000025138A3 Methods of diagnosing or prognosing alzheimer's disease |
| 08/24/2000 | WO2000023100A9 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 08/24/2000 | WO2000021987A9 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 08/24/2000 | WO2000020025A9 Akt compositions for enhancing survival of cells |
| 08/24/2000 | WO2000018917A9 α-SYNUCLEIN SUPER-MUTANTS ACCELERATE α-SYNUCLEIN AGGREGATION |
| 08/24/2000 | WO2000015797A3 Compositions and methods for the treatment of immune related diseases |
| 08/24/2000 | WO2000015246A9 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 08/24/2000 | WO2000015205A3 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes |
| 08/24/2000 | WO2000010611A3 Drug targeting |
| 08/24/2000 | WO1999042828A3 Treating cancer |
| 08/24/2000 | WO1998024898A3 Therapeutic composition comprising the kal protein and use of the kal protein |
| 08/24/2000 | DE19908753A1 Oligomer-polymer composition containing biodegradable polymers of hydroxycarboxylic acids, useful as injectable implant for administration of various drugs |
| 08/24/2000 | CA2371872A1 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | CA2362943A1 Pyk2 binding proteins |
| 08/24/2000 | CA2362787A1 Novel redox clamping agents and uses thereof |
| 08/24/2000 | CA2362334A1 Dibenzo-azepine derivatives as .alpha.v integrin receptor antagonists |
| 08/24/2000 | CA2362303A1 Growth hormone secretagogues |
| 08/24/2000 | CA2362300A1 Human lipid-associated proteins |
| 08/24/2000 | CA2362284A1 Modified calycins |
| 08/24/2000 | CA2361273A1 Inhibitors for use in hemostasis and immune function |
| 08/24/2000 | CA2328877A1 Composition for treatment of external secretion disorders except hypolacrimation |
| 08/23/2000 | EP1029853A1 Heteroaromatic bicyclic derivatives useful as anticancer agents |
| 08/23/2000 | EP1029547A1 Pharmaceutically active compounds and method for identifying same |
| 08/23/2000 | EP1029072A1 Method for identifying drug targets |
| 08/23/2000 | EP1029070A1 Transfecting peptide vector, composition containing same and applications |
| 08/23/2000 | EP1029062A1 Inhibition of human immunodeficiency virus (hiv-1) replication |
| 08/23/2000 | EP1029058A1 Dna demethylase, therapeutic and diagnostic uses thereof |
| 08/23/2000 | EP1029057A1 Reovirus-derived proteins, nucleic acids encoding same, and uses therefor |
| 08/23/2000 | EP1028848A1 Prepolymer compositions comprising an antimicrobial agent |
| 08/23/2000 | EP1028741A1 Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 08/23/2000 | EP1028732A1 Use of selected phytostenol esters for producing hypocholesteraemic preparations |